(a)
A physician and surgeon or other health care provider delivering fertility treatment shall provide his or her patient with timely, relevant, and appropriate information to allow the individual to make an informed and voluntary choice regarding the disposition of any human embryos remaining following the fertility treatment. The failure to provide to a patient this information constitutes unprofessional conduct within the meaning of Chapter 5 (commencing with Section 2000) of Division 2 of the Business and Professions Code.
(b)
Any individual to whom information is provided pursuant to subdivision (a) shall be presented with the option of storing any unused embryos, donating them to another individual, discarding the embryos, or donating the remaining embryos for research. When providing fertility treatment, a physician and surgeon or other health care provider shall provide a form to the male and female partner, or the individual without a partner, as applicable, that sets forth advanced written directives regarding the disposition of embryos. This form shall indicate the time limit on storage of the embryos at the clinic or storage facility and shall provide, at a minimum, the following choices for disposition of the embryos based on the following circumstances:
(1)
In the event of the death of either the male or female partner, the embryos shall be disposed of by one of the following actions:
(A)
Made available to the living partner.
(B)
Donation for research purposes.
(C)
Thawed with no further action taken.
(D)
Donation to another couple or individual.
(E)
Other disposition that is clearly stated.
(2)
In the event of the death of both partners or the death of a patient without a partner, the embryos shall be disposed of by one of the following actions:
(A)
Donation for research purposes.
(B)
Thawed with no further action taken.
(C)
Donation to another couple or individual.
(D)
Other disposition that is clearly stated.
(3)
In the event of separation or divorce of the partners, the embryos shall be disposed of by one of the following actions:
(A)
Made available to the female partner.
(B)
Made available to the male partner.
(C)
Donation for research purposes.
(D)
Thawed with no further action taken.
(E)
Donation to another couple or individual.
(F)
Other disposition that is clearly stated.
(4)
In the event of the partners’ decision or a patient’s decision who is without a partner, to abandon the embryos by request or a failure to pay storage fees, the embryos shall be disposed of by one of the following actions:
(A)
Donation for research purposes.
(B)
Thawed with no further action taken.
(C)
Donation to another couple or individual.
(D)
Other disposition that is clearly stated.
(c)
A physician and surgeon or other health care provider delivering fertility treatment shall obtain written consent from any individual who elects to donate embryos remaining after fertility treatments for research. For any individual considering donating the embryos for research, to obtain informed consent, the health care provider shall convey all of the following to the individual:
(1)
A statement that the early human embryos will be used to derive human pluripotent stem cells for research and that the cells may be used, at some future time, for human transplantation research.
(2)
A statement that all identifiers associated with the embryos will be removed prior to the derivation of human pluripotent stem cells.
(3)
A statement that donors will not receive any information about subsequent testing on the embryo or the derived human pluripotent cells.
(4)
A statement that derived cells or cell lines, with all identifiers removed, may be kept for many years.
(5)
Disclosure of the possibility that the donated material may have commercial potential, and a statement that the donor will not receive financial or any other benefits from any future commercial development.
(6)
A statement that the human pluripotent stem cell research is not intended to provide direct medical benefit to the donor.
(7)
A statement that early human embryos donated will not be transferred to a woman’s uterus, will not survive the human pluripotent stem cell derivation process, and will be handled respectfully, as is appropriate for all human tissue used in research.
